Incorporation of aggrecan in interpenetrating network hydrogels to improve cellular performance for cartilage tissue engineering

• Published in: Tissue engineering. Part A Vol. 19; no. 11-12; p. 1349
• Main Authors: Ingavle, Ganesh C, Frei, Anthony W, Gehrke, Stevin H, Detamore, Michael S
• Format: Journal Article
• Language: English
• Published: United States 01-06-2013
• Subjects: Aggrecans - pharmacology; Animals; Cartilage - cytology; Cartilage - drug effects; Cartilage - physiology; Cattle; Cell Survival - drug effects; Chondrocytes - cytology; Chondrocytes - drug effects; Chondrocytes - metabolism; Compressive Strength - drug effects; DNA - metabolism; Glycosaminoglycans - metabolism; Hydrogels - pharmacology; Hydroxyproline - metabolism; Male; Materials Testing; Microscopy, Confocal; Sus scrofa; Tissue Engineering - methods
• ISSN: 1937-335X
• DOI: 10.1089/ten.tea.2012.0160

Interpenetrating network (IPN) hydrogels were recently introduced to the cartilage tissue engineering literature, with the approach of encapsulating cells in thermally gelling agarose that is then soaked in a poly(ethylene glycol) diacrylate (PEGDA) solution, which is then photopolymerized. These IPNs possess significantly enhanced mechanical performance desirable for cartilage regeneration, potentially allowing patients to return to weight-bearing activities quickly after surgical implantation. In an effort to improve cell viability and performance, inspiration was drawn from previous studies that have elicited positive chondrogenic responses to aggrecan, the proteoglycan largely responsible for the compressive stiffness of cartilage. Aggrecan was incorporated into the IPNs in conservative concentrations (40 μg/mL), and its effect was contrasted with the incorporation of chondroitin sulfate (CS), the primary glycosaminoglycan associated with aggrecan. Aggrecan was incorporated by physical entrapment within agarose and methacrylated CS was incorporated by copolymerization with PEGDA. The IPNs incorporating aggrecan or CS exhibited over 50% viability with encapsulated chondrocytes after 6 weeks. Both aggrecan and CS improved cell viability by 15.6% and 20%, respectively, relative to pure IPNs at 6 weeks culture time. In summary, we have introduced the novel approach of including a raw material from cartilage, namely aggrecan, to serve as a bioactive signal to cells encapsulated in IPN hydrogels for cartilage tissue engineering, which led to improved performance of encapsulated chondrocytes.